AI English summary of an SEC filing — figures as filed
Bristol Myers Squibb BMYBristol Myers Squibb announced on July 25, 2025 that Dr. Samit Hirawat, Chief Medical Officer, will transition from his current role effective August 1, 2025 to become an advisor to the Company and will depart the Company on November 1, 2025.
Key points
AI summaryBristol Myers Squibb announced on July 25, 2025 that Dr. Samit Hirawat, Chief Medical Officer, will transition from his current role effective August 1, 2025 to become an advisor to the Company and will depart the Company on November 1, 2025.
The company said Dr. Hirawat will be entitled to severance benefits in accordance with the Company's U.S. Severance Benefits Plan, pro-rated vesting of Market Share Units (MSUs) and Performance Share Units (PSUs) in accordance with the Company's equity award agreements, and a prorated annual incentive payout for 2025 in accordance with the Company's Senior Executive Performance Incentive Plan.
Bristol Myers Squibb appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. He will oversee the company's early-stage and late-stage product development across all therapeutic areas and will report directly to Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer.
The company said Dr. Massacesi most recently served as Chief Medical Officer of AstraZeneca and Alexion and as Oncology Chief Development Officer at AstraZeneca, and prior to that held senior R&D positions at Pfizer and Novartis.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Dr. Hirawat to transition from role on August 1, 2025, depart on November 1
Bristol Myers Squibb announced on July 25, 2025 that Dr. Samit Hirawat, Chief Medical Officer, will transition from his current role effective August 1, 2025 to become an advisor to the Company and will depart the Company on November 1, 2025.
Source · Based on the filing body and exhibits
Hirawat severance: benefits, pro-rated MSU and PSU vesting, 2025 incentive
The company said Dr. Hirawat will be entitled to severance benefits in accordance with the Company's U.S. Severance Benefits Plan, pro-rated vesting of Market Share Units (MSUs) and Performance Share Units (PSUs) in accordance with the Company's equity award agreements, and a prorated annual incentive payout for 2025 in accordance with the Company's Senior Executive Performance Incentive Plan.
Source · Based on the filing body and exhibits
Massacesi appointed Chief Medical Officer, Head of Development as of August 1, 2025
Bristol Myers Squibb appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. He will oversee the company's early-stage and late-stage product development across all therapeutic areas and will report directly to Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer.
Source · Based on the filing body and exhibits
Massacesi: former CMO at AstraZeneca and Alexion, R&D roles at Pfizer and Novartis
The company said Dr. Massacesi most recently served as Chief Medical Officer of AstraZeneca and Alexion and as Oncology Chief Development Officer at AstraZeneca, and prior to that held senior R&D positions at Pfizer and Novartis.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…